Patents by Inventor Adrian KINZEL

Adrian KINZEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for treating tumors with TTFields and sorafenib
    Patent number: 11179322
    Abstract: Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: November 23, 2021
    Assignee: Novocure GmbH
    Inventors: Karnit Gotlib, Einav Zeevi, Rosa S. Schnaiderman, Tali Voloshin-Sela, Moshe Giladi, Adrian Kinzel, Eilon Kirson, Uri Weinberg, Yoram Palti, Shiri Davidi
  • Methods and Compositions for Treating Tumors with TTFields and Sorafenib
    Publication number: 20200016067
    Abstract: Viability of cancer cells (e.g., hepatocellular carcinoma cells) can be reduced by administering sorafenib to the cancer cells and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Viability of cancer cells (e.g., hepatocellular carcinoma cells) disposed in a body of a living subject can be reduced by administering sorafenib to the subject and applying an alternating electric field with a frequency between 100 and 400 kHz to the cancer cells. Notably, experiments show that the combination of sorafenib and the alternating electric field produces synergistic results both in vitro and in vivo.
    Type: Application
    Filed: July 9, 2019
    Publication date: January 16, 2020
    Applicant: Novocure GmbH
    Inventors: Karnit GOTLIB, Einav ZEEVI, Rosa S. SCHNAIDERMAN, Tali VOLOSHIN-SELA, Moshe GILADI, Adrian KINZEL, Eilon KIRSON, Uri WEINBERG, Yoram PALTI, Shiri DAVIDI